HOME >> MEDICINE >> NEWS
UIC developing drug for SARS

A prototype drug created by researchers at the University of Illinois at Chicago shows promise in slowing replication of the virus responsible for severe acute respiratory syndrome, or SARS.

Currently, there are no effective antiviral agents or vaccines for SARS, which killed almost 800 people in an epidemic in 2002-2003.

On the basis of their success, the researchers have received an $8 million grant from the National Institute of Allergy and Infectious Diseases to develop protease inhibitors that would block key enzymes in the SARS virus and hamper its advance. Protease inhibitors, a class of drugs capable of disrupting enzymes that digest proteins, have been successfully used to thwart the human immunodeficiency virus, which causes AIDS.

"Data from SARS patients indicate that replication of the virus peaks 10 days after the onset of fever," said Michael Johnson, director of the Center for Pharmaceutical Biotechnology in the UIC College of Pharmacy and the study's principal investigator. "By administering protease inhibitors early, when feverish symptoms have started, the drugs could reduce the viral load and ameliorate the disease."

Like HIV, the SARS virus multiplies rapidly, hijacking the machinery of the cells it infects to clone itself over and over again.

One of the first steps in that process is the production of a long chain of proteins, all of which are needed for the virus to propagate. Two enzymes, or proteases, clip the chain to release the individual proteins, the parts needed to assemble a mature virus.

These two proteases -- called 3CLpro and PLpro -- are UIC's targets for drug therapy.

"If we can block 3CLpro and probably PLpro, then we can stop the SARS virus from replicating," Johnson said.

Under the grant, Andrew Mesecar, associate professor of pharmacy, will study details of the three-dimensional structure of the two enzymes using x-ray crystallography.

His technique invol
'"/>

Contact: Sharon Butler
sbutler@uic.edu
312-355-2522
University of Illinois at Chicago
8-Jun-2005


Page: 1 2 3

Related medicine news :

1. Program announced to improve care in developing areas for patients with blood disorders
2. Caring for the sick now a public health priority for developing countries
3. Over time, more women are developing MS than men
4. Addressing the neglect of childhood hearing impairment in developing countries
5. First step in developing heart hormone-based pill to control high blood pressure
6. USC-led study suggests exercise reduces risk of developing invasive breast cancer
7. Cells passed from mother to child may be first step in developing new treatments for type 1 diabetes
8. Tuberculosis risks for health workers in developing countries
9. Global strategies to improve health in developing countries need truly global discussions
10. Adolescent smokers have a greater risk of developing alcohol-use disorders than nonsmokers
11. Measuring brain activity for emotional markers that may indicate risk for developing alcoholism

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: UIC developing drug for SARS

(Date:4/23/2014)... frozen stool from healthy, unrelated donors was safe ... diarrhea caused by Clostridium difficile , according ... Clinical Infectious Diseases and available online. Known ... effective whether given via a colonoscope or a ... make this promising treatment more readily available to ...
(Date:4/23/2014)... looking to give exercise enthusiasts the extra nudge they ... that a cyber buddy can help. , The study, ... , is the first to indicate that although a ... a software-generated partner also can be effective. , "We ... still motivate people to give greater effort while exercising ...
(Date:4/23/2014)... compound that targets an important brain receptor has a ... including relapse behavior, a University at Buffalo animal study ... this may be a novel lead compound for treating ... UB research was published as an online preview article ... study, the compound, RO5263397, severely blunted a broad range ...
(Date:4/23/2014)... (April 23, 2014) The American Gastroenterological Association ... 2014 AGA Research Scholars. The AGA Research Scholar ... to develop independent and productive research careers in ... Awards fund an additional year allowing for three ... to supporting junior faculty who are paving the ...
(Date:4/23/2014)... A team of scientists led by a researcher from ... the National University of Singapore has identified the cancer ... opens up the possibility of developing new drugs for ... cancers. , The research group, led by Dr Chan ... for the first time that a cancer-specific variant of ...
Breaking Medicine News(10 mins):Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:Cyber buddy is better than 'no buddy' 2Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:AGA announces 2014 Class of AGA Research Scholars 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... Jan. 15, 2014  Manufacturers, suppliers and distributors of ... to protect their most important business assets, intellectual ... ) Because of the highly-competitive nature ... one of the most litigious industry sectors of ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
Cached News: